US FDA approves Haegarda – a subcutaneous C1 esterase inhibitor for prevention of hereditary angioedema (HAE) attacks in paediatric patients

Approval was based on results from two trials (n=132) which showed Haegarda at the approved dose of 60 IU/kg, reduced the number of HAE attacks by a median of 95% and 97% respectively, relative to placebo.

Source:

Biospace Inc.